Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Actor Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (55)
Cancellation by sponsor (9)
Prescription medicine registration (5)
Australian Public Assessment Report (AusPAR) (2)
Prescription medicine decision summary (2)
Prescription medicine evaluation (1)

Date

2026 (23)
2025 (9)
2024 (13)
2023 (5)
2022 (3)
2021 (2)
2020 (1)
2019 (2)
2018 (1)
2017 (2)
2016 (3)
2015 (4)
2014 (2)
2005 (1)
2000 (1)
1991 (2)

Search

Sponsor content

74 result(s) found, displaying 11 to 20

ACTOSTARIN midostaurin 25 mg soft capsule blister pack (437376)

13 July 2026

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ACTOSTARIN midostaurin 25 mg soft capsule blister pack.
Axhidrox Actor Pharmaceuticals Pty Ltd

Jul-2026

Prescription medicine evaluation

Active ingredient: Glycopyrronium bromide.
Actor Pharmaceuticals Pty Ltd - Excilor Warts 2 in 1 Warts Treatment - Wart cryogenic kit Cancelled under Section 41GL(d) of the Act

5 June 2026

Cancellation by sponsor

Requested by Actor Pharmaceuticals Pty Ltd
TIBOGEN tibolone 2.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 June 2026

Cancellation by sponsor

Requested by Actor Pharmaceuticals Pty Ltd
RANIVIZ ranibizumab (rbe) 1.65 mg/0.165 mL solution for injection pre-filled syringe (475408)

27 February 2026

ARTG

Australian Register of Therapeutic Goods (ARTG) information for RANIVIZ ranibizumab (rbe) 1.65 mg/0.165 mL solution for injection pre-filled syringe.
Andriga

27 March 2026

Australian Public Assessment Report (AusPAR)

Andriga (abiraterone and prednisolone) has been approved for the treatment of prostate cancer.
ACTARIN (Actor Pharmaceuticals Pty Ltd)

19 March 2026

Prescription medicine registration

Active ingredients: midostaurin.
Actor Pharmaceuticals Pty Ltd - Skin moisturizing/barrier dressing Cancelled under Section 41GL(d) of the Act

4 March 2026

Cancellation by sponsor

Requested by Actor Pharmaceuticals Pty Ltd
Actor Pharmaceuticals Pty Ltd - Non-sterile scar management dressing, reusable Cancelled under Section 41GL(d) of the Act

4 March 2026

Cancellation by sponsor

Requested by Actor Pharmaceuticals Pty Ltd
Actor Pharmaceuticals Pty Ltd - Non-sterile scar management dressing, reusable Cancelled under Section 41GL(d) of the Act

4 March 2026

Cancellation by sponsor

Requested by Actor Pharmaceuticals Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.